Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (eg, asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational forum including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.